Annual Report
2015
Promoting world-class
biopharma investment
in Ireland
NIBRT Annual Report 2015
Contents
About NIBRT
4
Who we are
4
What we do
4
NIBRT’s vision
4
1.
Message from NIBRT CEO
4
2.
Message from NIBRT Chairman
6
3.
2015 NIBRT by the numbers
7
4. Growth of the Biopharma Industry
7
5.
Case study: Bristol-Myers Squibb
9
6.
Training and Education
10
7.
Research and Innovation
12
8.
Contract Research
14
9.
Events and Conferences
16
10. 2015 Awards
18
3
NIBRT Annual Report 2015
About NIBRT
Who we are
NIBRT is a world-class institute, based in
Dublin, Ireland whose mission is to deliver
training and research solutions for the global
biopharmaceutical manufacturing industry
NIBRT partners with industry to support
international best practice in all aspects of
biologics manufacturing
Become a global leader in
biopharmaceutical manufacturing
research, education and training
Opened in 2011, NIBRT’s research and training
building (6,500m2) features state-of-the-art pilot
scale manufacturing facilities
Build out our research and development
scale, capability and critical mass to
establish NIBRT as a globally recognised
centre for industry applied research and
process development
Established with IDA Ireland, NIBRT partners
with all higher education institutes to provide
training and research infrastructure facilitates
not previously available in Ireland
What we do
Train and educate over 3,800 people annually to
work in all areas of biopharma manufacturing
Collaborate with industry on scientific research
to drive biopharma innovation
Support major biopharma investment in Ireland
Provide a test bed for new technologies and
processes
4
NIBRT’s vision
Be the hub for bioprocessing
manufacturing research in Ireland and
internationally
Continue to support the growth and
development of the biopharmaceutical
industry in Ireland
NIBRT Annual Report 2015
1 Message from
NIBRT CEO
NIBRT has had another excellent year in 2015. It was
my first year as CEO and it has been a great pleasure
for me to join what is a very enthusiastic, dedicated
team and work to build on the excellent reputation
that NIBRT has attained to date.
Our areas of activity; training and
education, manufacturing research, and
contract research have all shown strong
growth over the last year.
In particular, the training needs of major
start-up biologics manufacturers were met
with significant programmes delivered
for Regeneron, Lilly and BioMarin. With
the new investments recently announced
in Ireland from Bristol-Myers Squibb,
Alexion, Mallinckrodt and others, the need
for skilled personnel and bioprocessing
training continues to grow. Indeed, the
industry is heading into a strong growth
phase and the demand for bioprocessing
talent is high. NIBRT, with its key
stakeholders, is focussed on ensuring
these skills needs are met. In addition to
the customised company specific training,
NIBRT prepared many graduates for
employment in the sector with its Skillnets,
Springboard and Education programmes.
Growth of the NIBRT research teams is a
priority, the current principal investigators
(PI) teams continue to develop rapidly
and the attraction of new PIs to NIBRT is
well advanced. Core research funding has
been secured from IDA Ireland for the next
5 years which allows greater investment
in the research teams. Many collaboration
projects with industry, vendors and other
institutes commenced during the year.
I would like to thank all the NIBRT
staff for their efforts in the strong 2015
performance. NIBRT comprises excellent
state-of-the-art facilities, but it is the
delivery of our research and training
solutions by our employees that drives our
success.
Dominic Carolan
CEO, NIBRT
5
NIBRT Annual Report 2015
2Message from
NIBRT Chairman
Ireland continues to be an attractive location for
global biopharma investment, thanks to the continued
efforts and strong partnership from all stakeholders
across Industry, Academia and Government.
Key to this success is ensuring the
availability of a highly educated and well
trained workforce to support the needs
of the industry. The strategic decision by
the Irish Government and IDA Ireland to
invest in NIBRT continues to pay fruitful
dividends in ensuring the continued
availability of this talent pool to meet
the growing needs of new investors,
established companies and emerging
indigenous biotechs alike. In this respect,
NIBRT has recorded its strongest year
ever in 2015, with all areas of activity
recording strong revenue growth and
more people trained than ever before. I am
particularly proud of NIBRT’s work in the
area of Skillnets and Springboard training,
providing opportunities for employment
in this growth sector through appropriate
cross training and upskilling for those with
valued experience in other sectors.
2015 was also a year of significant change
for NIBRT, with the appointment of a new
CEO in Dominic Carolan and a number
of changes at Board level, to support
the Institute’s commitment to growing
it’s research capabilities and services,
complementing the strong competencies
that have been developed to date in the
provision of world class training solutions
to the biopharma industry, both on-line
and in-class.
6
The company structures that have
been established, coupled with the
open-architecture model that is being
encouraged across all academic centres
active in the biotech arena, will enable
the Institute build on the strong research
foundations that exist today, but with
greater momentum as we build out our
scale and specific areas of competence.
I am particularly grateful to the Irish
Government for their commitment to
sustained funding for NIBRT research over
the coming years.
I would like to thank those outgoing
Board members (Prof Briain MacCraith,
Prof Vinny Cahill, Ger O’Mahony, Eucharia
Meehan, Michael Kamarck and Dr Reg
Shaw) for their outstanding support to
NIBRT through these recent transitions.
Most of all, I would like to thank Dominic
and all his staff, the dedicated employees
of NIBRT, for their continued commitment
to the mission of the Institute and the
clients we serve. It is your talent and
commitment that give me confidence in
the ability of NIBRT to meet the growing
needs of the biopharma sector, both
locally in Ireland and further afield.
Brendan O’Callaghan,
Chairman, NIBRT
NIBRT Annual Report 2015
32015 NIBRT by the numbers
2015 NIBRT BY THE NUMBERS
92%
% OF NIBRT’S COSTS THAT
ARE COVERED BY INCOME
NIBRT GENERATES
3,800
NUMBER OF TRAINEES IN 2015
17,480
NUMBER OF TRAINING
DAYS DELIVERED 15%
INCREASE FROM 2014
22%
% OF TRAINING
WHICH IS
INTERNATIONAL
91%
47%
% OF DAYS TRAINING
OCCURRED IN NIBRT
FACILITY
% OF NIBRT
RESEARCH
THAT IS
FUNDED BY
INDUSTRY
646
24
NUMBER OF
SPRINGBOARD
STUDENTS TRAINED
IN 2015
NUMBER OF
CONFERENCES
HELD IN NIBRT
1,565
NUMBER OF
ATTENDEES
AT NIBRT
CONFERENCES
4Growth of the Biopharma
Industry
18
BIOPHARMA
MANUFACTURING
SITES IN IRELAND
$9 BILLION
OF CAPITAL
INVESTMENT IN
LAST DECADE
7
NIBRT Annual Report 2015
The biopharmaceutical
industry in Ireland is
going through a period of
unprecedented growth and
development.
BIOPHARMA
INVESTMENTS IN 2015
Since 2005 there has been $9 billion in
capital investment via IDA companies1 in
the biopharma industry. The number of
biopharma manufacturing sites in Ireland
has risen from 2 in 2003 to 18 in 2015,
contributing to €39 billion in lifescience
exports in 20132.
From a global perspective,
“biopharmaceuticals generate revenues
of $163 billion, making up about 20
percent of the pharma market. It’s by far
the fastest-growing part of the industry:
biopharma’s current annual growth rate
of more than 8 percent is double that
of conventional pharma, and growth is
expected to continue at that rate for the
foreseeable future”3.
There is currently a global shortage of
biopharma skills4,5 and NIBRT’s role in
providing access to skilled talent is a
key determinant in attracting biopharma
foreign direct investment.
Regeneron Announces an additional
$350 million Investment and
200 New Jobs in Limerick by End-20176
Pfizer announces 130 jobs across Irish
operations over next year7
Amgen opens new $300
facility8
million
PAREXEL Opens a Global DecisionMaking Hub in Dublin9
Mallinckrodt to create 45 new
with €45million investment10
jobs
Nexvet secures Biomanufacturing
Facility in Tullamore11
Alexion Pharmaceuticals announces
€450 million expansion in Dublin –
200 new jobs and 800 construction jobs
to be created over four years12
Horizon Pharma plc celebrates official
opening of new Global Corporate
headquarters in Dublin13
ABEC Inc. to establish European HQ
and manufacturing centre in Fermoy,
Co. Cork, creating up to 100 new jobs14
1.http://www.idaireland.com/how-we-help/resources/infographics/biopharmaceutical-industr/index.xml
2. Annual Business Survey of Economic Impact 2013 (ABSEI)
3.http://www.mckinsey.com/insights/health_systems_and_services/rapid_growth_in_biopharma
4. BioPlan’s 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
5. UK Needs Biomanufacturing Skills, Association of the British Pharmaceutical Industry (ABPI), 2015
6.http://www.idaireland.com/newsroom/regeneron-announces-an-ad/
7.http://www.pfizer.ie/news/2015/10/23/pfizer-announces-130-jobs-across-irish-operations-over-next-year
8.http://www.idaireland.com/newsroom/amgen/index.xml
9.http://www.idaireland.com/newsroom/parexel/
10.http://www.irishtimes.com/business/health-pharma/mallinckrodt-to-create-45-new-jobs-with-45m-investment-1.2219289
11.http://www.idaireland.com/business-in-ireland/industry-sectors/bio-pharmaceuticals/
12.http://www.idaireland.com/newsroom/alexion-pharmaceuticals-a/
13.http://www.idaireland.com/newsroom/horizon-pharma-plc-celebr/
14.http://www.idaireland.com/newsroom/abec-inc.-to-establish-eu/
8
NIBRT Annual Report 2015
5Case study
Bristol-Myers Squibb
BMS Staff at NIBRT for Careers in BMS event, November 2015.
In November 2014, Bristol-Myers Squibb (BMS) announced plans to
construct a new state-of-the-art, large-scale biologics manufacturing
facility in Cruiserath, County Dublin that will produce multiple
therapies for the company’s growing biologics portfolio.
350 to 400 manufacturing jobs and about
2,000 construction jobs are expected to be
created. BMS are now working closely with
NIBRT to help hire and training their employees
for this landmark investment.
The cutting-edge, 30,000 square metre project
will house six 15,000 litre bioreactors and a
purification area, as well as contemporary office
and laboratory space. The plant will be built
on the grounds of the company’s existing bulk
pharmaceutical manufacturing plant, and is
planned as one of the most accelerated built
plants of this size and specification in history.
The new high-tech campus will have modern
laboratory amenities. BMS employees will be
able to work and collaborate with other teams
on the floor, and their work will truly make a
difference to patient’s lives.
The new Dublin facility at Cruiserath represents
a significant investment in the local area, and
BMS has been an established presence in
Ireland for more than 50 years. This investment
provides opportunities to potential and existing
employees, as well as offering careers in a
place that supports best-in-class systems and
processes, and is always striving for continuous
improvement.
BMS are hiring now with staff increasing to
around 400 roles by 2019 across many business
functions, including manufacturing, quality and
manufacturing, science and technology (MS&T).
With a healthy pipeline of products, BMS are
dedicated to providing excellent opportunities
for growth and career development. A company
with a strong commitment to top quality
people management, BMS believe in passion,
accountability, innovation and speed.
9
NIBRT Annual Report 2015
6Training and Education
Amgen trainees at NIBRT.
In addition to training industry directly,
NIBRT works closely with the Higher
Education Institutes to ensure there
is a strong supply of graduates in
Ireland with the skills required for the
biopharma and related sectors.
Industry Training
2015 was a very busy and productive year for NIBRT
training. We were pleased to deliver over 17,000 learning
days to 3,800 trainees. Key clients include Abbvie,
Alexion, Allergan, Amgen, Astellas, BioMarin, Bioquell,
Genzyme, Ecolab, Janssen Biologics, Eli Lilly, Pfizer,
Regeneron, Sanofi Genzyme, Sartorius Stedim Biotech,
Pfizer, Thermo Scientific.
Skilled Graduates
In 2015, NIBRT partnered with 12 Higher Education
Institutes to deliver practical and experiential training
to their students including University College Dublin,
Dublin City University, Institute of Technology Sligo,
Trinity College Dublin, Dundalk Institute of Technology,
Dublin Institute of Technology, Cork Institute of
Technology, Institute of Technology Tallaght, Galway Mayo
Institute of Technology, National University of Ireland
Galway, University of Limerick and Limerick Institute of
Technology.
10
Ireland is rapidly becoming a
very important centre for the global
biopharmaceutical sector. A highly
skilled workforce will be essential to
support this.
As the IBEC sector group that
represents the pharmaceutical,
biologics and biopharma
manufacturers in Ireland, we are
glad to support the development of
such an important programme and
to see NIBRT plays such valuable
role in providing the necessary
training for these employees.
Matt Moran, Director,
PharmaChemical Ireland
NIBRT Annual Report 2015
Jobseekers
In 2015, NIBRT partnered with six Higher
Education Institutes to provide free training
programmes to over 600 jobseekers under the
Springboard+ programme. On average, 65%
of NIBRT trainees secure employment after
participating in these very popular courses
which are designed to meet the needs of the
fast growing biopharma industry.
2015 TRAINING
BY THE NUMBERS
DELIVERED TO
17,480 3,800
TRAINING DAYS
TRAINEES
22%
OF TRAINING WITH
AN INTERNATIONAL
AUDIENCE
International Clients
International clients who travelled to NIBRT to
access the state-of-the-art pilot plant facilities
accounted for 22% of our 2015 training clientele.
This included the provision of a global training
programme with AbbVie for Key Opinion
Leaders and Health Care Practitioners.
NIBRT’s partnership with North Eastern
University, MA, USA continued with
undergraduate students travelling to NIBRT for
training in biopharmaceuticals as part of their
final year programme.
New Industry Masterclasses
In 2015 NIBRT partnered with Steris Technical
services to deliver a new program in Applied
Cleaning Validation Procedures which offered
industrial practitioners in the validation space
the opportunity to engage with subject matter
experts and to discuss case studies and best
practices. Theory sessions were complimented
with direct hands-on practical sessions using
state-of-the-art bioprocessing equipment
located in the NIBRT production training facility.
Suppliers
NIBRT partnered with several vendors to install
new equipment in the NIBRT facility including
the Bioquell’s Qube M19, which is a four-glove
aseptic workstation with two glove separated
decontamination unit and a material transfer
device. It is fully integrated with rapid hydrogen
peroxide vapour (HPV) decontamination to
deliver ISO5 / Grade A conditions.
OVER
600
JOBSEEKERS
RECEIVING
FREE TRAINING
PROGRAMMES
2,534
5,548
2,354
TRAINING
DELIVERED ON
91%
OF
AVAILABLE
DAYS
HOT LUNCHES SERVED
TEAS/COFFEES SERVED
SANDWICH ORDERS
NIBRT had a huge impact
on my employability for this
sector. My learning with NIBRT
has really allowed me to hit the
ground running, as the course
was so specific to the job I actually
perform. It is hands down the best
decision I have made so far in terms
of career progression. I would 100%
recommend this course, it’s a no
brainer.
Testimonial from
Springboard student
11
NIBRT Annual Report 2015
7Research and Innovation
Damien English TD, Minister for Skills, Research and Innovation with Anna Lindberg, BioMarin and NIBRT CEO
Dominic Carolan at NIBRT’s Opportunities in Biopharma Research Conference, September 2015.
NIBRT research provides access to leading scientists in world class
facilities to address key issues in the manufacture of innovative
biologic medicines.
Bioinformatics
and Data Analytics
Following the award of a prestigious SFI Starting
Investigator Research Grant (SIRG) in 2014, Dr.
Colin Clarke’s CHO cell bioinformatics team is
now firmly established at NIBRT. The NIBRT
Bioinformatics and Data Analytics Laboratory
specialises in the application of multivariate
statistics and machine learning algorithms for
the analysis of complex CHO cell biological
datasets. Dr. Clarke’s team have been actively
building a number of high profile academic (e.g.
University of California at San Diego and Johns
Hopkins University) and industry collaborations
since his arrival.
Host Cell Protein Removal
Work funded through Dr Jonathan Bones’ SFI
SIRG award has applied a proteomic platform to
evaluate the removal of host cell proteins (HCPs)
from monoclonal antibody samples following
Protein A purification.
12
Amy Farrell, a NIBRT PhD candidate working on
this project, won a CASSS Mass Spec Student
Travel Grant to present these findings at 11th
Symposium on the Practical Applications of Mass
Spectrometry in the Biotechnology Industry in
Napa, CA, USA (Sept 2014). Dr. Bones was also
invited to present this work at the Biological
Production Forum in Dusseldorf in March 2015.
This work was published in the peer-reviewed
research journal Analytical Chemistry in 2015.
The technology is available as to a contract
research offering through NIBRT.
NIBRT is the only dedicated biopharma
research and training institute in the world.
The Institute plays a key part in positioning
Ireland as a location of choice for international
biopharma development projects.
Martin Shanahan,
CEO, IDA Ireland
NIBRT Annual Report 2015
PATsule - Irish Invention
could Revolutionise
Production of Future
Medicine
In 2015, Drs. Jonathan Bones (NIBRT)
and Karen Twomey (Tyndall National
Institute) launched the interdisciplinary PATsule project. The two
year project was funded through the
Enterprise Ireland Commercialisation
Fund to develop wireless sensor
capsules for bioreactor monitoring.
This project is the first collaborative
effort between the two Institutes
and has attracted significant media
coverage16,17. The PATsule was also
included on Silicon Republic’s list of
the 10 Irish breakthrough innovations
of 201518.
2015 RESEARCH
BY THE NUMBERS
47%
OF NIBRT RESEARCH
IS DIRECTLY FUNDED
BY INDUSTRY
TOTAL RESEARCH
INCOME FROM
INDUSTRY 2011-2015
€4.4 million
Inaugural Opportunities
in Biopharma Research
The inaugural “Opportunities in
Biopharma Research” event was held
in NIBRT on 29th September 2015.
The event attracted approximately
100 delegates, 33 of whom were
industry representatives.
Over 20 posters were presented at
the event with NIBRT researchers
securing the SFI-funded poster prizes
in both the postgraduate category
(Craig Monger, Dr. Clarke research
group) and the post doctorate
category (Drs. Noemi Dorival
Garcia and Christine Ta, both part
of Dr. Bones’ research group).
Dr Jonathan Bones (NIBRT) and Dr Karen Twomey (Tyndall National Institute).
15. Farrell, A., Mittermayr, S., Morrissey, B., McLoughlin, N., Iglesias, N.N., Marison, I.W., Bones, J. Quantitative Host Cell Protein
Analysis Using Two Dimensional Data Independent LC-MSE, Analytical Chemistry, 87(18), p.9186-9193, 2015
16.http://www.theengineer.co.uk/more-sectors/medical/news/wireless-sensor-capsules-monitor-production-ofbiopharmaceuticals/1021299.article
17.http://www.biopharma-reporter.com/Upstream-Processing/Irish-research-hubs-invent-roaming-reactor-sensor
18.https://www.siliconrepublic.com/innovation/2015/12/29/10-irish-breakthrough-innovations-of-2015-that-are-a-bit-special
13
NIBRT Annual Report 2015
8Contract Research
Barry Heavey, Head of Life Sciences, IDA Ireland; Marcella Corcoran Kennedy TD; Minister Damien English TD;
Mark Heffernan, CEO Nextvet and ‘Duffer’ the dog announcing NextVet’s investment in Tullamore, September 2015.
NIBRT Contract Research offers a range of bespoke analytical
services to the biopharmaceutical industry.
Glycan analysis
New services in 2015
Glycan analysis services continue to be in high
demand with NIBRT’s N-Glycan and O-Glycan
services offerings now including;
The expansion of analytical platforms for
protein analysis continues in 2015 with service
offering now including:
Glycan profiling studies- quantitative glycan
comparison between product batches and
comparison of biosimilars.19
Glycan characterisation- structural elucidation
to reveal detailed glycan composition of
products.
Glycan site occupancy- occupancy site
identification and percentage occupancy
determination.
Intact Protein analysis-mass accurate
measurement of the product or product
subcomponents e.g. mAb heavy and light
chains.
Post Translation Modification profilingquantitative comparison of PTMs between
product batches and comparison of
biosimilars.
Peptide sequencing.
Analytical Ultra Centrifugation-quantification
of product aggregates.
19.Martin, S.M., Delporte, C., Farrell, A., Iglesias, N.N., McLoughlin, N., Bones, J., Comparative analysis of monoclonal antibody
N-glycosylation using stable isotope labelling and UPLC-fluorescence-MS, The Analyst, 140(5), p.1442-7, 2015
14
NIBRT Annual Report 2015
Host Cell Protein Analysis
Following on from ground breaking
publication20 by Dr Bones team, NIBRT is
delighted to offer
Identification of Host Cell Proteins
present in the product and
simultaneous quantification using the
Hi-3 MSe approach.
Targeted quantification of known Host
Cell Proteins using multiple reaction
monitoring- mass spectrometry.
NEW IN 2016 -
HYDROGEN DEUTERIUM
EXCHANGE MASS
SPECTROMETRY ANALYSIS
Epitope mapping
Protein-drug binding
Protein-protein interactions
Aggregation studies
The NIBRT building.
Ireland is the ideal place to grow our business. It has great
infrastructure, routes to market, expansion opportunities and
the availability of highly skilled personnel along with a strong
scientific community and access to the National Institute of
Bioprocessing Research and Training (NIBRT) capabilities.
Mr. Jean-Jacques Bienaime,
Chief Executive Officer,
BioMarin Pharmaceutical Inc
20. Farrell, A., Mittermayr, S., Morrissey, B., McLoughlin, N., Iglesias, N.N., Marison, I.W., Bones, J. Quantitative Host Cell Protein
Analysis Using Two Dimensional Data Independent LC-MSE, Analytical Chemistry, 87(18), p.9186-9193, 2015
15
NIBRT Annual Report 2015
9Events and Conferences
Minister Bruton TD, Minister for Jobs, Enterprise & Innovation with NIBRT Springboard students at NIBRT’s
Careers in Biopharma event, April 2015.
In 2015, NIBRT hosted 24 events with over 1,560 thousand
attending. Some notable events included:
In February and September 2015, NIBRT hosted
the Biocluster zone at CareerZoo, Ireland’s
foremost careers events for professionals and
innovative employers. Over 20,000 people
attended both events at the National Convention
Centre which included exhibitors from BMS,
Regeneron, Alexion, Amgen, MSD, PPD, Janssen
Biologics, Sanofi Genzyme, NextVet, Pfizer.
NIBRT was delighted to partner with Informa to
see the return of the leading industry conference
Bioproduction 2015 to CityWest, Dublin in
October 2015. Featuring over 400 attendees
BioProduction provides the platform for the key
biologic manufacturers from across Europe, and
the rest of the World to discuss their plans to
both advance and refine this evolving industry.
16
Working closely with BMS, the “Career Open
Day for BMS” was held on Saturday Nov 21st
2015 in NIBRT with over 500 attendees.
35 journalists from 22 countries attended
the global NIBRT-AbbVie event “Managing
Complexity: the new biologics landscape”,
in Nov 24-25th 2015.
In March 2015, NIBRT in partnership with IDA
and Enterprise Ireland hosted “Biopharma
Manufacturing Competitiveness - driving
competitiveness via innovative supplier
relationships”. This unique event featured
seminars and networking events between
buyers and suppliers.
NIBRT Annual Report 2015
DATE
2015 EVENTS
PARTNER
Feb
NIBRT Biocluster at CareerZoo
CareerZoo
March
Biopharma Manufacturing Competitiveness:
Driving competitiveness via innovative supplier relationships
IDA, EI, ISPE
April
NIBRT Careers in Biopharma
NIBRT
May
Disposable Solutions for Fill Finish Operations
DPS Engineering, Saint-Gobain, Colder Products Company and
BPSA
Micro Industries
August
Moving Beyond Industry 3.0
ATS
Sept
NIBRT Biocluster at CareerZoo
CareerZoo
Oct
Opportunities in Biopharma Research
PCI
Oct
Bioproduction 2015
Informa
Nov
Managing Complexity: the new biologics landscape
AbbVie
Nov
Bristol-Myers Squibb Careers Day at NIBRT
BMS
My NIBRT experience was
transformative. As an industry
professional with 10 years’
experience in BioPharma, NIBRT
offered a training course that
I had never seen in the field
previously. Expertly balanced
in theory and practice, the
course centred on hands-on
practicals that mirrored what
Trainees could expect in reallife manufacturing facilities.
The result was highly-engaged,
knowledgeable individuals with
new-found confidence through
learning by doing. I would
recommend NIBRT’s course
offerings having personally
experienced the positive effect it
has had on my career.
Anne Marie Molloy,
NIBRT student
NIBRT laboratories.
17
NIBRT Annual Report 2015
10 2015 Awards
Winners of three awards
at Irish Pharma Awards:
Pharma Education and Training Award
Partnership Alliance of the Year
Pharma Leader of the Year
Other Awards:
LifeSciences 50 Award, Business
and Finance magazine: Dr Reg Shaw
(outgoing CEO NIBRT)
American Chamber of Commerce Ireland
US- Ireland Research Innovation Awards
2015, shortlist: Prof Pauline Rudd NIBRTWaters collaboration.
Silicon Republic’s list of the 10 Irish
breakthrough innovations of 2015:
NIBRT’s PATsule partnership with Tyndall
18
www.nibrt.ie
Foster Avenue, Mount Merrion,
Blackrock, Co. Dublin, Ireland.
Tel: +353 1 215 8100
Fax: +353 1 215 8116
Email: [email protected]